# Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant

> **NCT00456482** · PHASE2,PHASE3 · TERMINATED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 239 (actual)

## Conditions studied

- Non-infectious Uveitis

## Interventions

- **DRUG:** Fluocinolone Acetonide 0.59mg
- **DRUG:** Fluocinolone Acetonide 2.1mg

## Key facts

- **NCT ID:** NCT00456482
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-05
- **Primary completion:** 2006-04
- **Final completion:** 2006-04
- **Target enrollment:** 239 (ACTUAL)
- **Why stopped:** SARS epidemic in Asia and Canada
- **Last updated:** 2011-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00456482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00456482, "Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00456482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*